MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Recro Pharma Company Profile (NASDAQ:REPH)

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.33 (221.77% upside)

Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetActions
11/24/2015HC WainwrightReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2015Brean CapitalReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015HC WainwrightInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015Brean CapitalReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2015Brean CapitalInitiated CoverageBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Brean CapitalBoost Price TargetBuy$26.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2015Brean CapitalSet Price TargetBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2015MLV & Co.Boost Price TargetBuy$12.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2015Brean CapitalReiterated RatingBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014AegisDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/5/2014AegisLower Price Target$40.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2014AegisInitiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/19/2014Brean CapitalInitiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/10/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha